The German pharmaceutical laboratory BioNTech, which works with Pfizer, expects “in two weeks at the latest” the first results of research that will determine whether the new variant found in South Africa is capable of escaping the protection provided by vaccines. , said his spokesman.
“We immediately started investigations into variant B.1.1.529” which “is clearly different from the already known variants because it shows additional mutations in the spike protein”, characteristic of the SARS-CoV-2 virus, the spokeswoman explained to AFP.
“Pfizer and BioNTech have been ready for several months to adjust their vaccine in less than six weeks and deliver the first doses in 100 days,” if a variation proves durable.
Source: AMPE
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
